A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer
一项 1 期临床试验的扩展，旨在评估晚期胰腺癌患者使用 VXM01（一种针对 VEGFR2 的口服 T 细胞疫苗）进行初免-加强接种的免疫效果和安全性
期刊:Oncoimmunology
影响因子:
doi:10.1080/2162402X.2017.1303584
Friedrich H Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, Lilli Podola, Tobias Friedrich, Heinz Lubenau, Marco Springer, Sébastien Wieckowski, Klaus M Breiner, Gerd Mikus, Markus W Büchler, Anne-Valerie Keller, Ruhan Koc, Christoph Springfeld, Phillip Knebel, Mariana Bucur, Lars Grenacher, Wa
